These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26757613)

  • 41. Etravirine.
    Knoll BM; Vento S; Temesgen Z
    Drugs Today (Barc); 2008 Jan; 44(1):23-33. PubMed ID: 18301801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
    Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
    J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Kiertiburanakul S; Wiboonchutikul S; Sukasem C; Chantratita W; Sungkanuparph S
    J Clin Virol; 2010 Apr; 47(4):330-4. PubMed ID: 20188624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
    Lyseng-Williamson KA
    Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
    AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).
    Rusconi S; Adorni F; Bruzzone B; Di Biagio A; Meini G; Callegaro A; Punzi G; Boeri E; Pecorari M; Monno L; Gianotti N; Butini L; Galli L; Polilli E; Galli M;
    Clin Microbiol Infect; 2013 Oct; 19(10):E443-6. PubMed ID: 23621421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of the safety and tolerability profile of the next-generation NNRTI etravirine.
    Grinsztejn B; Di Perri G; Towner W; Woodfall B; De Smedt G; Peeters M
    AIDS Res Hum Retroviruses; 2010 Jul; 26(7):725-33. PubMed ID: 20624073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine.
    Carbone A; Bigoloni A; Galli L; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    AIDS; 2013 Oct; 27(16):2661-3. PubMed ID: 24096632
    [No Abstract]   [Full Text] [Related]  

  • 55. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
    ; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
    AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
    Pou C; Noguera-Julian M; Pérez-Álvarez S; García F; Delgado R; Dalmau D; Álvarez-Tejado M; Gonzalez D; Sayada C; Chueca N; Pulido F; Ibáñez L; Rodríguez C; Casadellà M; Santos JR; Ruiz L; Clotet B; Paredes R
    Clin Infect Dis; 2014 Aug; 59(4):578-88. PubMed ID: 24879788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
    Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
    HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.